Researchers have developed an AI-powered tool called PhenopyCell that can predict how patients with extensive-stage Small Cell Lung Cancer will respond to platinum-based chemotherapy before treatment begins. This is important because about 70% of patients are diagnosed at an advanced stage, and doctors currently lack reliable biomarkers to guide treatment decisions.
The tool works by analyzing standard biopsy slides that are already collected during diagnosis. It examines how immune cells are arranged around tumor cells. Patients with well-organized immune cells close to tumors tend to respond better to chemotherapy, while those with scattered or distant immune cells are less likely to benefit. Because it uses existing slides, no additional biopsies or testing are needed, saving both time and cost.
PhenopyCell has shown higher accuracy than traditional manual analysis. This allows doctors to identify patients who may not benefit from standard chemotherapy and instead guide them earlier toward clinical trials or newer treatments. Developed by researchers from Roswell Park Comprehensive Cancer Center and Emory University, the tool represents a major step toward personalized care by helping match the right treatment to patients during a critical window when time is limited.